

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Marc G. Jacquemin &
Jean-Marie R. Saint-Remy

Serial No.: 10/044,569

Filed: January 11, 2002

Patent: Method and Pharmaceutical
Composition for Preventing
and/or Treating Systemic
Inflammatory Response
Syndrome



Examiner: Not yet assigned

Group Art Unit: 1645

I hereby certify that this correspondence is being
deposited with the United States Postal Service as first
class mail in an envelope addressed to "Commissioner for
Patents, Box: Missing Parts, Washington, D.C. 20231" on
April 10, 2002. Name of person signing Terri Dickinson

Signature

Honorable Director of Patents and Trademarks
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

REQUEST FOR CORRECTION OF FILING RECEIPT

Dear Sir:

Attached is a copy of the filing receipt for Application No. 10/044,569 with changes noted thereon. The filing receipt indicates only one inventor (Marc G. Jacquemin), however, as is evident from the Declaration submitted herewith, Jean-Marie R. SAINT-REMY is also an inventor. Thus, the inventors are as follows:

Marc G. Jacquemin
45, Rue Morimont
B-5330 Sart-Bernard
Belgium

Jean-Marie R. Saint-Remy
79, Rue du Lambais
B-1390 Grez-Doiceau
Belgium


Further, the Domestic Priority Data as claimed by Applicant and Foreign Applications were improperly left blank. The present application is a continuation-in-part of now identified U.S. Application No. 10/030,522 filed December 31, 2001, which is a 35 U.S.C. §371 application based on PCT/EP00/06677 filed July 13, 2000 that in turn claims priority from GB

9916450.1 and U.S. Application No. 60/143,891, both filed July 14, 1999. The present application also claims priority from U.S. Application No. 60/261,405 filed January 11, 2001.

Applicants respectfully request issuance of a corrected filing receipt as outlined herein.

Respectfully submitted,

April 10, 2002
Date



Mark A. Hagedorn
Reg. No. 44,731
Lee, Mann, Smith, McWilliams,
Sweeney & Ohlson
P.O. Box 2786
Chicago, Illinois 60690-2786
312-368-5945 Direct Line
312-368-0034 Facsimile

One of the Attorneys for Applicant



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/044,569	01/11/2002	1645	379	522-1769.1	10	21	3

CONFIRMATION NO. 9454

FILING RECEIPT



OC00000007516602

Mark A. Hagedorn
Lee, Mann, Smith, McWilliams, Sweeney, & Ohlson
Suite 410
209 S. LaSalle St.
Chicago, IL 60604



Date Mailed: 02/22/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

-- 45 Rue Morimont, B-5330 Sart-Benard, Belgium --

Marc G. Jacquemin, [Residence Not Provided]

-- Jean-Marie R. Saint-Remy, 79 Rue du Tambais, B-1390 Grez-Doreau, Belgium --

Domestic Priority data as claimed by applicant.

This Application claims benefit of U.S. Application 10/030,522 (Dec. 31, 2001), which is a 371 application based on PCT/EP00/06677 (July 13, 2000), and U.S. Application 60/261,405 (Jan. 11, 2001). --

Foreign Applications

GB 9916450.1 (July 14, 1999)

RECEIVED
LEE, MANN, SMITH,
MCWILLIAMS, SWEENEY & OHLSON

If Required, Foreign Filing License Granted 02/21/2002

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Marc G. Jacquemin &
Jean-Marie R. Saint-Remy

Serial No.: 10/044,569

Filed: January 11, 2002

Patent: Method and Pharmaceutical
Composition for Preventing
and/or Treating Systemic
Inflammatory Response
Syndrome



Examiner: Not yet assigned

Group Art Unit: 1645

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to "Commissioner for Patents, Box: Missing Parts, Washington, D.C. 20231" on April 10, 2002.

Name of person signing Terri Dickinson

Signature [Signature]

RESPONSE TO NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

Honorable Director of Patents
and Trademarks
Washington, D.C. 20231

Dear Sir:

In response to the Notice to file Missing Parts of Nonprovisional Application, issued February 22, 2002, submitted herewith is a declaration, signed by the inventor(s). Therefore, the requirement of the Patent and Trademark Office for a declaration has been met. In accordance with the provisions of the rules of the Patent and Trademark Office, the required surcharge of \$65.00 is appended hereto.

In further response to the Notice to File Missing Parts, submitted herewith are two substitute copies (1.44 Mb 3.5" diskettes labeled "Copy 1" and "Copy 2") of the "Sequence Listing" in computer readable form. The content of the sequence listing information recorded

in computer readable form is identical to the written sequence listing and includes no new matter.

April 10, 2002

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Mark A. Hagedorn', written over a horizontal line.

Mark A. Hagedorn
Registration No. 44,731
Lee, Mann, Smith, McWilliams,
Sweeney & Ohlson
P.O. Box 2786
Chicago, Illinois 60690-2786
(312) 368-6620
(312) 368-0034 (fax)

3



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/044,569	01/11/2002	Marc G. Jacquemin	522-1769.1

CONFIRMATION NO. 9454

FORMALITIES LETTER



OC000000007521944

Mark A. Hagedorn
Lee, Mann, Smith, McWilliams, Sweeney, & Ohlson
Suite 410
209 S. LaSalle St.
Chicago, IL 60604



Date Mailed: 02/22/2002

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

04/17/2002 TBESHAH1 00000067 10044569

FILED UNDER 37 CFR 1.53(b)

01 FC:205

65.00 0P

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is missing.
A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(l) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 65.**
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov